Schéma : This study is a randomized, open-label, international, multi-center, phase 2 study in patients with Heregulin-positive NSCLC histologically classified as adenocarcinoma that have progressed following no more than two systemic therapies for locally advanced or metastatic disease, one of which must have been a platinum containing regimen. All patients will initially be screened for heregulin status. Eligible patients will be randomized to receive MM-121 in combination with docetaxel versus docetaxel alone.
Study Arms:

Experimental: Arm A: Experimental Arm
MM-121 in combination with Docetaxel
Interventions:
Drug: MM-121
Drug: Docetaxel
Active Comparator: Arm B: Comparator Arm
Docetaxel alone
Intervention: Drug: Docetaxel